Clinical Trials Logo

Macrophage Activation Syndrome clinical trials

View clinical trials related to Macrophage Activation Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04339712 Completed - COVID-19 Clinical Trials

Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction

ESCAPE
Start date: April 2, 2020
Phase: Phase 2
Study type: Interventional

Our aim is to conduct one trial of personalized immunotherapy in patients with SARS-CoV-2 (COVID-19) associated with organ dysfunction and with laboratory findings of macrophage activation syndrome or immune dysregulation. These patients will be selected by the use of a panel of biomarkers and laboratory findings and they will be allocated to immunotherapy treatment according to their needs.

NCT ID: NCT03332225 Completed - Sepsis Clinical Trials

A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis

PROVIDE
Start date: December 15, 2017
Phase: Phase 2
Study type: Interventional

The aim of the study is to conduct one RCT of personalized immunotherapy in sepsis targeting patients who lie either on the predominantly hyper-inflammatory arm or on the predominantly hypo-inflammatory arm of the spectrum of the host response. These patients will be selected by the use of a panel of biomarkers and laboratory findings and they will be randomly allocated to placebo or immunotherapy treatment according to their needs.

NCT ID: NCT03311854 Completed - Clinical trials for Macrophage Activation Syndrome

A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

Start date: February 20, 2018
Phase: Phase 2
Study type: Interventional

Macrophage Activation Syndrome (MAS) is a rare, life-threatening condition characterized by uncontrolled hyperinflammation which may develop on the background of systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD). Emapalumab is a monoclonal antibody neutralizing interferon-gamma (IFN-gamma), a key cytokine which contributes to the inflammation and tissue damage seen in MAS. The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in sJIA or AOSD participants developing MAS, presenting an inadequate response to high dose glucocorticoid treatment.

NCT ID: NCT02854943 Completed - Clinical trials for Hemophagocytic Lymphohistiocytosis (HLH)

Investigation of Ferritin in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis

FERRITS
Start date: January 2000
Phase:
Study type: Observational

Retrospective analysis of ferritin, outcome and HLH-criteria in critically ill patients.